Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 6, 2016, Pages 677-685

  Oba, Yuji ^a   Chandran, Arul V ^a   Devasahayam, Joe V ^a  

^a University of Missouri   (United States)

Author keywords

Bronchodilator agents; drug related side effects and adverse reactions; outcome assessment (health care); pneumonia; quality of life; respiratory function tests

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE ASSESSMENT TEST SCORE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; INCIDENCE; MEDICAL HISTORY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITIONAL DYSPNEA INDEX; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84965005781     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2016.1170799     Document Type: Article

References (29)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379(9823):1341–1351. Epub 2012/02/09.
2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–65. Epub 2012/08/11.
3. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting:an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014; 9:889–904. Epub 2014/09/12.
4. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829. Epub 2012/09/14.
5. Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med 2012; 18(1):85–89. Epub 2011/11/25.
6. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD:a network meta-analysis. Thorax 2015; 71(1):15–25. Epub 2015/10/23.
7. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371(14):1285–1294. Epub 2014/09/10.
8. Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-source UPLIFT(R) trial. Lung 2011; 189(4):261–268. Epub 2011/06/17.
9. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines:a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64(4):380–382. Epub 2010/12/28.
10. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates:meta-epidemiological study. BMJ 2013; 346:f2304. Epub 2013/04/26.
11. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials:meta-epidemiological study. BMJ 2010; 341:c3515. Epub 2010/07/20.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557–560. Epub 2003/09/06.
13. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 2011; 64(12):1283–1293. Epub 2011/08/16.
14. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten A, et al. Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD. Eur Respir J 2015; 46(suppl 59):PA2960.
15. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN:a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015; 10:1015–1026. Epub 2015/06/18.
16. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1(1):51–60. Epub 2013/12/11.
17. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015; 109(7):870–881. Epub 2015/05/27.
18. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD:a randomised trial. BMC Pulm Med 2015; 15:91. Epub 2015/08/20.
19. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189(3):250–255. Epub 2014/01/05.
20. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD Assessment Test:a prospective analysis. Lancet Respir Med 2014; 2(3):195–203. Epub 2014/03/14.
21. Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist:observational matched cohort study (PATHOS). BMJ 2013; 346:f3306. Epub 2013/05/31.
22. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010; 340:c117. Epub 2010/04/01.
23. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease:a systematic review and meta-analysis. JAMA 2008; 300(20):2407–2416. Epub 2008/11/27.
24. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease:a meta-analysis. Arch Intern Med 2009; 169(3):219–229. Epub 2009/02/11.
25. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, et al. Budesonide and the risk of pneumonia:a meta-analysis of individual patient data. Lancet 2009; 374(9691):712–719. Epub 2009/09/01.
26. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3:CD010115. Epub 2014/03/13.
27. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD:the clinical evidence. Eur Respir J 2015; 45(2):525–537. Epub 2014/12/30.
28. Novartis Pharmaceuticals. QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study. ClinicalTrials.gov. Available from:https://clinicaltrials.gov/ct2/show/NCT01782326 (accessed 21December2015).
29. GlaxoSmithKline. A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). ClinicalTrials.gov. Available from:https://clinicaltrials.gov/ct2/show/NCT02164513 (accessed 21December2015).